Presentation

Company Profile
Cantargia AB is a Swedish biotechnology company that specialises in the development of antibody-based treatments for various types of cancer and autoimmune/inflammatory diseases. The company’s lead asset Nadunolimab (CAN04), works by activating the tumour growth. The target molecule, IL-1RAP, is expressed in most of the common forms of cancer. Nadunolimab is currently being investigated in 3 clinical studies in different cancer indications and combination therapies, with two more expected to commence in H2 2021. A preclinical project, the antibody CAN10, addresses treatment of autoimmune/inflammatory diseases, and plans are to initiate the first clinical programme in H1 2022. The firm is headquartered in Lund, Sweden.

Recent highlights
Positive interim results were presented from the CANFOUR study showing an improved progression-free survival and overall survival for combination treatment with CAN04 and chemotherapy in pancreatic cancer, compared to historical control data. Furthermore, A letter of intent was signed with GEICAM to conduct a clinical study with CAN04 in combination with carboplatin/gemcitabine in triple negative breast cancer. The company also announced that an application was submitted to start a new phase Ib clinical study on combination treatment with CAN04 and FOLFIRINOX in pancreatic cancer.

Outlook
The company’s focus for 2021 is to continue the clinical development of CAN04. 2 studies are expected to initiate in Q3 and Q4 respectively, while the CANFOUR and CIRIFOUR studies are expected to be finalised in Q3.